<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770848</url>
  </required_header>
  <id_info>
    <org_study_id>20070611</org_study_id>
    <nct_id>NCT00770848</nct_id>
  </id_info>
  <brief_title>AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The primary objectives of this study are the following:

      Phase 1b: To identify a safe dose level of AMG 102, up to 15 mg/kg Q3W, to combine with
      mitoxantrone and prednisone (MP) Phase 2: To estimate with adequate precision the effect of
      the addition of AMG 102 to MP, compared with placebo plus MP, as assessed by the hazard ratio
      (HR) for overall survival (OS) of previously treated subjects with castrate-resistant
      prostate cancer (CRPC)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b - Incidence of adverse events defined by dose-limiting toxicities</measure>
    <time_frame>21 days after the 6th subjects has recieved 1st cycle of AMG 102 in combination with MP</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Overall survival</measure>
    <time_frame>Entire Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b - Incidence of adverse events, abnormal laboratory values not defined as dose limiting toxicities</measure>
    <time_frame>Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b - Incidence of anti-AMG 102 antibody formation</measure>
    <time_frame>Entire Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b - Cmax and Cmin of AMG 102 concentration</measure>
    <time_frame>Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Progression-free survival</measure>
    <time_frame>Entire Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Maximum percentage reduction in PSA level</measure>
    <time_frame>Entire Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - PSA response rate (≥50% reduction in PSA values from baseline)</measure>
    <time_frame>Entire Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Objective response rate (CR and PR per RECIST with modifications)</measure>
    <time_frame>Entire Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Patient Report Outcome including pain-specific measures</measure>
    <time_frame>Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Incidence of adverse events and significant laboratory value changes from baseline</measure>
    <time_frame>Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Incidence of anti-AMG 102 antibody formation</measure>
    <time_frame>Entire Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Cmax and Cmin of AMG 102; Cmax and AUC for Mitoxantrone</measure>
    <time_frame>Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Percentage change in PSA levels from baseline to 12 weeks (or earlier for those who discontinue therapy)</measure>
    <time_frame>Treatment Period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Cancer</condition>
  <condition>Castrate-Resistant Prostate Cancer</condition>
  <condition>Mestastatic Prostate Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1b - AMG 102</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 1b is an open-label study with AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed, will be administered by IV Q3W in combination with MP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm A - AMG 102 + MP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 102 safe dose level in phase 1b in combination with MP, will be administered by IV Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm C- PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with MP, will be administered by IV Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm B - AMG 102 + MP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safe dose level in phase 1b of AMG 102 + MP will be administered by Q3W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 102</intervention_name>
    <description>Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.</description>
    <arm_group_label>Phase 2 Arm A - AMG 102 + MP</arm_group_label>
    <arm_group_label>Phase 2 Arm B - AMG 102 + MP</arm_group_label>
    <other_name>Rilotumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 102</intervention_name>
    <description>Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.</description>
    <arm_group_label>Phase 1b - AMG 102</arm_group_label>
    <other_name>Rilotumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Administered Q3W for a maximum of 12 cyles</description>
    <arm_group_label>Phase 1b - AMG 102</arm_group_label>
    <arm_group_label>Phase 2 Arm A - AMG 102 + MP</arm_group_label>
    <arm_group_label>Phase 2 Arm C- PLACEBO</arm_group_label>
    <arm_group_label>Phase 2 Arm B - AMG 102 + MP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Phase 2 Arm C- PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>5 mg orally BID</description>
    <arm_group_label>Phase 1b - AMG 102</arm_group_label>
    <arm_group_label>Phase 2 Arm A - AMG 102 + MP</arm_group_label>
    <arm_group_label>Phase 2 Arm C- PLACEBO</arm_group_label>
    <arm_group_label>Phase 2 Arm B - AMG 102 + MP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed adenocarcinoma of the prostate

          -  Radiographic evidence of metastatic disease

          -  Progressive disease meeting at least one of the following criteria:

               1. a sequence of at least 2 rising PSA values measured at a minimum of 1 week apart
                  with a 2 ng/mL minimum starting value, or

               2. progression according to RECIST criteria for measurable lesions, or

               3. appearance of 2 or more new lesions on bone scan.

          -  History of prior taxane-based chemotherapy for metastatic prostate cancer

          -  For patients without a history of surgical castration, continued GnRH analog
             administration is required

          -  ECOG Performance status of 0 or 1

          -  Life expectancy ≥ 3 months

        Exclusion Criteria:

          -  Treatment with external beam radiotherapy ≤ 14 days before enrollment or
             radiopharmaceutical ≤8 weeks

          -  ≤ 4 weeks since receipt of most recent prior chemotherapy, non-GnRH analog hormonal
             therapy (except for continuing corticosteroids) or other systemic therapy to treat
             prostate cancer and &lt;6 weeks since receipt of prior bevacizumab.

          -  Known CNS metastases (epidural disease is allowed if it has been treated and there is
             no progression in the treated area).

          -  Significant cardiovascular disease

          -  LVEF &lt; 50% by MUGA or ECHO

          -  Treatment of infection with systemic anti-infectives within 7 days before enrollment
             (with the exception of uncomplicated urinary tract infection)

          -  Concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except that
             use of low dose coumarin-type anticoagulants or heparins for prophylaxis against
             central venous catheter thrombosis is allowed

          -  Major surgical procedure ≤30 days before enrollment or not yet recovered from prior
             major surgery

          -  Presence of peripheral edema &gt; Grade 2

          -  Known positive test for HIV, hepatitis C, chronic or active hepatitis B

          -  Serious or non-healing wound

          -  Unable to begin protocol specified treatment within 7 days after enrollment

          -  Other investigational procedures are excluded.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Oliner K.BM Ph2 CRPC.Journal-004521;</citation>
  </reference>
  <reference>
    <citation>Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24. doi: 10.1158/1078-0432.CCR-12-2605. Epub 2012 Nov 7.</citation>
    <PMID>23136195</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <disposition_first_submitted>April 15, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 15, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 23, 2013</disposition_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

